Prediction of Preeclampsia Utilizing Biomarker and Clinical Factors

Salt Lake City, March 18, 2022 —Sera Inc., The Pregnancy
Company ® (Nasdaq: SERA), focused on improving maternal and neonatal health
by providing innovative pregnancy biomarker information to doctors and patients,
today presented data demonstrating the effective prediction of preeclampsia
using protein biomarkers and clinical factors. The presentation titled
“Comparison of Protein Biomarkers to Clinical Factors for Preeclampsia in Two
Cohorts” was given by lead author Julja Burchard et al this morning at the 69th
Annual Meeting of the Society for Reproductive Investigation (SRI) in Denver,
Colorado, during Late Breaking Session LB-002 from 9:00-10:30 AM.

This study was a secondary analysis of two large independent pregnancy cohorts
totaling more than 10,500 enrolled patients, PAPR (NCT01371019; 11 U.S. sites,
2011-2013) and TREETOP (NCT02787213; 18 U.S. sites, 2016-2018)
investigating the ability of 6 clinical factors and 31 protein biomarkers to predict
either preeclampsia at any gestational age or preterm preeclampsia occurring
before 37 weeks of pregnancy in women prior to receiving a clinical diagnosis of
preeclampsia. Of the 6 clinical factors, only having had preeclampsia in a prior
pregnancy was significantly predictive of both outcomes in both studies. Of 31
biomarkers, significant prediction of preeclampsia and preterm preeclampsia
was shown by 7 and 5 biomarkers, respectively, in both studies. Biomarkers,
paired with the clinical predictor preeclampsia in a previous pregnancy, showed
additive predictive performance and contributed more strongly for prediction of
preterm preeclampsia. Biomarkers alone, whether or not clinical factors are
available, also showed independent predictive performance of preeclampsia,
enabling more timely interventions designed to address a patient’s individual risk.

“We are pleased to have this important study completed on preeclampsia, a
major cause of prematurity and neonatal and maternal health complications,”
said Gregory C. Critchfield, MD, MS, Chairman and Chief Executive Officer of Sera
Prognostics. “This study, conducted by leading researchers in maternal-fetal
medicine, demonstrates progress on our pipeline and our ongoing commitment to providing valuable information to doctors and pregnant women in Sera
Prognostics’ journey as The Pregnancy Company.”

About Sera, Inc.
Sera is a leading health diagnostics company dedicated to
improving the lives of women and babies through precision pregnancy care.
Sera’s mission is to deliver early, pivotal information in pregnancy to physicians,
enabling them to improve the health of their patients, resulting in reductions in
the costs of healthcare delivery. Sera has a robust pipeline of innovative
diagnostic tests focused on the early prediction of preterm birth risk and other
complications of pregnancy. Sera’s precision medicine PreTRM ® Test reports to a
physician the individualized risk of spontaneous premature delivery in a
pregnancy, enabling earlier proactive interventions in women with higher risk.
Sera is located in Salt Lake City, Utah

About Preterm Birth
Preterm birth is defined as any birth before 37 weeks’ gestation and is the
leading cause of illness and death in newborns. The 2021 March of Dimes Report
Card shows that more than one in ten infants is born prematurely. Prematurity is
associated with a significantly increased risk of major long-term medical
complications, including learning disabilities, cerebral palsy, chronic respiratory
illness, intellectual disability, seizures, and vision and hearing loss, and can
generate significant costs throughout the lives of affected children. The annual
health care costs to manage short- and long-term complications of prematurity in
the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM^® Test
The PreTRM^® test is the only broadly validated, commercially available blood-
based biomarker test that provides an early, accurate and individualized risk
prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
The PreTRM^® test measures and analyzes proteins in the blood that are highly
predictive of preterm birth. The PreTRM^® test permits physicians to identify,
during the 19th or 20th week of pregnancy, which women are at increased risk
for preterm birth, enabling more informed, personalized clinical decisions based
on each woman’s individual risk. The PreTRM^® test is ordered by a medical
professional.

Sera, the Sera logo, The Pregnancy Company, and
PreTRM are trademarks or registered trademarks of Sera, Inc. in the
United States and/or other countries.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to progress on the company’s pipeline; and the company’s strategic
directives under the caption “About Sera, Inc.” These “forward-
looking statements” are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth in or implied
by forward-looking statements. These risks and uncertainties include, but are not
limited to: net losses, cash generation, and the potential need to raise more
capital; revenues from the PreTRM test representing substantially all Company
revenues to date; the need for broad scientific and market acceptance of the
PreTRM test; a concentrated number of material customers; our ability to
introduce new products; potential competition; our proprietary biobank; critical
suppliers; the ongoing COVID-19 pandemic and its impact on our operations, as
well as the business or operations of third parties with whom we conduct
business; estimates of total addressable market opportunity and forecasts of
market growth; potential third-party payer coverage and reimbursement; new
reimbursement methodologies applicable to the PreTRM test, including new CPT
codes and payment rates for those codes; changes in FDA regulation of
laboratory-developed tests; the intellectual property rights protecting our tests
and market position; and other factors discussed under the heading “Risk
Factors” contained in our Final Prospectus on Form S-1, which was filed with the
Securities and Exchange Commission on July 14, 2021, as well as any updates to
those risk factors filed from time to time in our Quarterly Reports on Form 10-Q,
Annual Reports on Form 10-K, or Current Reports on Form 8-K. All information in
this press release is as of the date of the release, and the Company undertakes
no duty to update this information unless required by law.

Investor Contact
Peter DeNardo, CapComm Partners
peter@capcommpartners.com
+1 (415) 389-6400

Media Contact
Erich Sandoval, Lazar FINN
Erich.sandoval@finnpartners.com
+1 (917) 497-2867